ClinicalTrials.gg

Program

NTQ5082

A development code. Also written as “NTQ5082 capsules 200 mg”, “NTQ5082 100mg qd” and “NTQ5082 200mg qd”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA, led by Sino Biopharmaceutical.

Furthest: phase 3, since Sep 10, 20256 company-led studies, 6 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical66 open or runningphase 3since Sep 10, 2025Jul 23, 2024Nov 2026phase 3 · NCT07177859

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2024First studies: 2 phase 1 studies in Complement-mediated Hemolytic DiseasesFirst studyNCT06560593, NCT06558656
  2. Dec 24, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06764303 · 24 enrolled · China
  3. May 12, 2025Phase 2 study in Glomerulonephritis, IGANCT06982040 · 80 planned
  4. Sep 10, 20252 phase 3 studies in Hemoglobinuria, ParoxysmalNCT07177872, NCT07177859

Ahead

  1. Nov 2026Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07177859
  2. Jun 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07177872

TargetBeta

CFB →read by rule
“NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade.”study text, by rule · the study

Other programs on CFB

ProgramCompanyFurthest phaseStudies
iptacopanruleNovartisphase 325
HRS-5965Jiangsu HengRui Medicinephase 314
FXS6837Fosun Pharmaphase 34
sefaxersenHoffmann-La Rochephase 31
HS-10542Hansoh Pharmaceutical Groupphase 23
FWY003Novartisphase 21
SAR446597Sanofiphase 21

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07177872Hemoglobinuria, Paroxysmal · China3Not yet recruitingJun 202878
NCT07177859Hemoglobinuria, Paroxysmal · China3Not yet recruitingNov 202678
NCT06982040Glomerulonephritis, IGA2Not yet recruitingSep 202680
NCT06764303Hemoglobinuria, Paroxysmal · China2Active, not recruitingJul 8, 202524
NCT06560593Complement-mediated Hemolytic Diseases · China1Not yet recruitingDec 202482
NCT06558656Complement-mediated Hemolytic Diseases · China1Not yet recruitingDec 202412

How it is read

Names in the registry

  • “NTQ5082 capsules 200 mg”, 3 entries
  • “NTQ5082 100mg qd”, 1 entry
  • “NTQ5082 200mg qd”, 1 entry
  • “NTQ5082 capsules 100 mg”, 1 entry
  • “NTQ5082 capsules 300 mg”, 1 entry

Codes read as this program: NTQ5082.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.